Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VcR-CAP vs R-CHOP in Newly Diagnosed Mantle Cell Lymphoma
NCT00722137Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- May 2008
- Primary completion
- Jan 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of bortezomib in mantle cell lymphoma (MCL) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Progression Free Survival at 40 months. Started May 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00722137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00722137.